Medications to Treat Opioid Use Disorder Research Report

  1. Substance Abuse Center for Behavioral Health Statistics and Quality. Results from the 2020 National Survey on Drug Use and Health: Detailed Tables. SAMHSA. Published October 25, 2021. Accessed November 29, 2021.
  2. Centers for Disease Control and Prevention. Prescription Opioids Overview. Published March 17, 2021. Accessed April 5, 2021.
  3. CDC WONDER. Multiple Cause of Death 1999-2021. Centers for Disease Control and Prevention, National Center on Health Statistics. Released January 2023. Accessed January 2023.
  4. Patrick SW, Davis MM, Lehmann CU, Lehman CU, Cooper WO. Increasing incidence and geographic distribution of neonatal abstinence syndrome: United States 2009 to 2012. J Perinatol Off J Calif Perinat Assoc. 2015;35(8):650-655. doi:10.1038/jp.2015.36.
  5. Tolia VN, Patrick SW, Bennett MM, et al. Increasing incidence of the neonatal abstinence syndrome in U.S. neonatal ICUs. N Engl J Med. 2015;372(22):2118-2126. doi:10.1056/NEJMsa1500439.
  6. Conrad C, Bradley HM, Broz D, et al. Community Outbreak of HIV Infection Linked to Injection Drug Use of Oxymorphone--Indiana, 2015. MMWR Morb Mortal Wkly Rep. 2015;64(16):443-444.
  7. U.S. Department of Health and Human Services, Office of the Assistant Secretary for Planning and Evaluation. Opioid Abuse in the U.S. and HHS Actions to Address Opioid-Drug Related Overdoses and Deaths. ASPE. Published November 23, 2015. Accessed May 11, 2017.
  8. Wheeler E, Jones TS, Gilbert MK, Davidson PJ, Centers for Disease Control and Prevention (CDC). Opioid Overdose Prevention Programs Providing Naloxone to Laypersons - United States, 2014. MMWR Morb Mortal Wkly Rep. 2015;64(23):631-635.
  9. Knudsen HK, Abraham AJ, Roman PM. Adoption and implementation of medications in addiction treatment programs. J Addict Med. 2011;5(1):21-27. doi:10.1097/ADM.0b013e3181d41ddb.
  10. Bart G. Maintenance medication for opiate addiction: the foundation of recovery. J Addict Dis. 2012;31(3):207-225. doi:10.1080/10550887.2012.694598.
  11. Davoli M, Bargagli AM, Perucci CA, et al. Risk of fatal overdose during and after specialist drug treatment: the VEdeTTE study, a national multi-site prospective cohort study. Addict Abingdon Engl. 2007;102(12):1954-1959. doi:10.1111/j.1360-0443.2007.02025.x.
  12. Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009;(3):CD002209. doi:10.1002/14651858.CD002209.pub2.
  13. Mattick RP, Breen C, Kimber J, Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. Cochrane Database Syst Rev. 2014;(2):CD002207. doi:10.1002/14651858.CD002207.pub4.
  14. Substance Abuse and Mental Health Services Administration. Clinical Guidelines for the Use of Buprenorphine in the Treatment of Opioid Addiction: A Treatment Improvement Protocol TIP 40. Substance Abuse and Mental Health Services Administration; 2004. Accessed May 11, 2017.
  15. The American Society of Addiction Medicine. Advancing Access to Addiction Medications. Accessed May 11, 2017.
  16. Yancovitz SR, Des Jarlais DC, Peyser NP, et al. A randomized trial of an interim methadone maintenance clinic. Am J Public Health. 1991;81(9):1185-1191.
  17. Vanichseni S, Wongsuwan B, Choopanya K, Wongpanich K. A controlled trial of methadone maintenance in a population of intravenous drug users in Bangkok: implications for prevention of HIV. Int J Addict. 1991;26(12):1313-1320.
  18. Schwartz RP, Highfield DA, Jaffe JH, et al. A randomized controlled trial of interim methadone maintenance. Arch Gen Psychiatry. 2006;63(1):102-109. doi:10.1001/archpsyc.63.1.102.
  19. Kinlock TW, Gordon MS, Schwartz RP, O’Grady K, Fitzgerald TT, Wilson M. A randomized clinical trial of methadone maintenance for prisoners: results at 1-month post-release. Drug Alcohol Depend. 2007;91(2-3):220-227. doi:10.1016/j.drugalcdep.2007.05.022.
  20. Dolan KA, Shearer J, MacDonald M, Mattick RP, Hall W, Wodak AD. A randomised controlled trial of methadone maintenance treatment versus wait list control in an Australian prison system. Drug Alcohol Depend. 2003;72(1):59-65.
  21. Schwartz RP, Kelly SM, O’Grady KE, Gandhi D, Jaffe JH. Randomized trial of standard methadone treatment compared to initiating methadone without counseling: 12-month findings. Addict Abingdon Engl. 2012;107(5):943-952. doi:10.1111/j.1360-0443.2011.03700.x.
  22. Sees KL, Delucchi KL, Masson C, et al. Methadone maintenance vs 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA. 2000;283(10):1303-1310.
  23. Gruber VA, Delucchi KL, Kielstein A, Batki SL. A randomized trial of 6-month methadone maintenance with standard or minimal counseling versus 21-day methadone detoxification. Drug Alcohol Depend. 2008;94(1-3):199-206. doi:10.1016/j.drugalcdep.2007.11.021.
  24. Fiellin DA, Schottenfeld RS, Cutter CJ, Moore BA, Barry DT, O’Connor PG. Primary care-based buprenorphine taper vs maintenance therapy for prescription opioid dependence: a randomized clinical trial. JAMA Intern Med. 2014;174(12):1947-1954. doi:10.1001/jamainternmed.2014.5302.
  25. Kakko J, Svanborg KD, Kreek MJ, Heilig M. 1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial. Lancet Lond Engl. 2003;361(9358):662-668. doi:10.1016/S0140-6736(03)12600-1.
  26. Fudala PJ, Bridge TP, Herbert S, et al. Office-based treatment of opiate addiction with a sublingual-tablet formulation of buprenorphine and naloxone. N Engl J Med. 2003;349(10):949-958. doi:10.1056/NEJMoa022164.
  27. MacDonald K, Lamb K, Thomas ML, Khentigan W. Buprenorphine Maintenance Treatment of Opiate Dependence: Correlations Between Prescriber Beliefs and Practices. Subst Use Misuse. 2016;51(1):85-90. doi:10.3109/10826084.2015.1089905.
  28. Nunes EV, Krupitsky E, Ling W, et al. Treating Opioid Dependence With Injectable Extended-Release Naltrexone (XR-NTX): Who Will Respond? J Addict Med. 2015;9(3):238-243. doi:10.1097/ADM.0000000000000125.
  29. Minozzi S, Amato L, Vecchi S, Davoli M, Kirchmayer U, Verster A. Oral naltrexone maintenance treatment for opioid dependence. Cochrane Database Syst Rev. 2011;(4):CD001333. doi:10.1002/14651858.CD001333.pub4.
  30. Krupitsky E, Nunes EV, Ling W, Gastfriend DR, Memisoglu A, Silverman BL. Injectable extended-release naltrexone (XR-NTX) for opioid dependence: long-term safety and effectiveness. Addict Abingdon Engl. 2013;108(9):1628-1637. doi:10.1111/add.12208.
  31. Krupitsky E, Nunes EV, Ling W, Illeperuma A, Gastfriend DR, Silverman BL. Injectable extended-release naltrexone for opioid dependence: a double-blind, placebo-controlled, multicentre randomised trial. Lancet Lond Engl. 2011;377(9776):1506-1513. doi:10.1016/S0140-6736(11)60358-9.
  32. Syed YY, Keating GM. Extended-release intramuscular naltrexone (VIVITROL®): a review of its use in the prevention of relapse to opioid dependence in detoxified patients. CNS Drugs. 2013;27(10):851-861. doi:10.1007/s40263-013-0110-x.
  33. Jackson H, Mandell K, Johnson K, Chatterjee D, Vanness DJ. Cost-Effectiveness of Injectable Extended-Release Naltrexone Compared With Methadone Maintenance and Buprenorphine Maintenance Treatment for Opioid Dependence. Subst Abuse. 2015;36(2):226-231. doi:10.1080/08897077.2015.1010031.
  34. World Health Organization. Proposal for the Inclusion of Buprenorphine in the WHO Model List of Essential Medicines.; 2004. Accessed May 11, 2017.
  35. World Health Organization. Proposal for the Inclusion of Methadone in the WHO Model List of Essential Medicines. World Health Organization; 2004. Accessed May 11, 2017.
  36. Williams JT, Ingram SL, Henderson G, et al. Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol Rev. 2013;65(1):223-254. doi:10.1124/pr.112.005942.
  37. Allouche S, Noble F, Marie N. Opioid receptor desensitization: mechanisms and its link to tolerance. Front Pharmacol. 2014;5:280. doi:10.3389/fphar.2014.00280.
  38. Walsh SL, June HL, Schuh KJ, Preston KL, Bigelow GE, Stitzer ML. Effects of buprenorphine and methadone in methadone-maintained subjects. Psychopharmacology (Berl). 1995;119(3):268-276.
  39. Highlights of Prescribing Information: SUBOXONE®. February 2017.  Accessed May 11, 2017.
  40. Kosten TR, George TP. The neurobiology of opioid dependence: implications for treatment. Sci Pract Perspect. 2002;1(1):13-20.
  41. Cruciani RA, Knotkova H, eds. Handbook of Methadone Prescribing and Buprenorphine Therapy. New York: Springer-Verlag; 2013.
  42. Brunton LL, Lazo JS, Parker KL, eds. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 11th ed.
  43. U.S. Department of Justice Drug Enforcement Administration, Office of Diversion Control. National Forensic Laboratory Information System (NFLIS) 2013 Annual Report. Accessed May 11, 2017.
  44. Bazazi AR, Yokell M, Fu JJ, Rich JD, Zaller ND. Illicit use of buprenorphine/naloxone among injecting and noninjecting opioid users. J Addict Med. 2011;5(3):175-180. doi:10.1097/ADM.0b013e3182034e31.
  45. Schuman-Olivier Z, Albanese M, Nelson SE, et al. Self-treatment: illicit buprenorphine use by opioid-dependent treatment seekers. J Subst Abuse Treat. 2010;39(1):41-50. doi:10.1016/j.jsat.2010.03.014.
  46. Cicero TJ, Surratt HL, Inciardi J. Use and misuse of buprenorphine in the management of opioid addiction. J Opioid Manag. 2007;3(6):302-308.
  47. Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. Factors contributing to the rise of buprenorphine misuse: 2008-2013. Drug Alcohol Depend. 2014;142:98-104. doi:10.1016/j.drugalcdep.2014.06.005.
  48. Johnson B, Richert T. Diversion of methadone and buprenorphine from opioid substitution treatment: a staff perspective. J Psychoactive Drugs. 2014;46(5):427-435. doi:10.1080/02791072.2014.960109.
  49. Johnson B, Richert T. Diversion of methadone and buprenorphine by patients in opioid substitution treatment in Sweden: prevalence estimates and risk factors. Int J Drug Policy. 2015;26(2):183-190. doi:10.1016/j.drugpo.2014.10.003.
  50. Duffy P, Mackridge AJ. Use and diversion of illicit methadone – under what circumstances does it occur, and potential risks associated with continued use of other substances. J Subst Use. 2014;19(1-2):48-55. doi:10.3109/14659891.2012.734539.
  51. Soyka M. New developments in the management of opioid dependence: focus on sublingual buprenorphine-naloxone. Subst Abuse Rehabil. 2015;6:1-14. doi:10.2147/SAR.S45585.
  52. Center for Behavioral Health Statistics and Quality (CBHSQ). Drug Abuse Warning Network: 2011: Selected Tables of National Estimates of Drug-Related Emergency Department Visits. Rockville, MD: Substance Abuse and Mental Health Services Administration; 2013.
  53. Substance Abuse and Mental Health Services Administration. Drug Abuse Warning Network, 2011: National Estimates of Drug-Related Emergency Department Visits. Published May 2013. Accessed May 12, 2017.
  54. Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality (CBHSQ). The DAWN Report: Emergency Department Visits Involving Buprenorphine. Substance Abuse and Mental Health Services Administration; 2013. Accessed May 12, 2017.
  55. Centers for Disease Control and Prevention (CDC). Vital signs: risk for overdose from methadone used for pain relief - United States, 1999-2010. MMWR Morb Mortal Wkly Rep. 2012;61(26):493-497.
  56. Metzger DS, Donnell D, Celentano DD, et al. Expanding substance use treatment options for HIV prevention with buprenorphine-naloxone: HIV Prevention Trials Network 058. J Acquir Immune Defic Syndr 1999. 2015;68(5):554-561. doi:10.1097/QAI.0000000000000510.
  57. Perlman DC, Jordan AE, Uuskula A, et al. An international perspective on using opioid substitution treatment to improve hepatitis C prevention and care for people who inject drugs: Structural barriers and public health potential. Int J Drug Policy. 2015;26(11):1056-1063. doi:10.1016/j.drugpo.2015.04.015.
  58. Otiashvili D, Piralishvili G, Sikharulidze Z, Kamkamidze G, Poole S, Woody GE. Methadone and buprenorphine-naloxone are effective in reducing illicit buprenorphine and other opioid use, and reducing HIV risk behavior--outcomes of a randomized trial. Drug Alcohol Depend. 2013;133(2):376-382. doi:10.1016/j.drugalcdep.2013.06.024.
  59. Malta M, Strathdee SA, Magnanini MMF, Bastos FI. Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic review. Addict Abingdon Engl. 2008;103(8):1242-1257. doi:10.1111/j.1360-0443.2008.02269.x.
  60. Batki SL, Gruber VA, Bradley JM, Bradley M, Delucchi K. A controlled trial of methadone treatment combined with directly observed isoniazid for tuberculosis prevention in injection drug users. Drug Alcohol Depend. 2002;66(3):283-293.
  61. Gowing L, Farrell MF, Bornemann R, Sullivan LE, Ali R. Oral substitution treatment of injecting opioid users for prevention of HIV infection. Cochrane Database Syst Rev. 2011;(8):CD004145. doi:10.1002/14651858.CD004145.pub4.
  62. Gowing LR, Hickman M, Degenhardt L. Mitigating the risk of HIV infection with opioid substitution treatment. Bull World Health Organ. 2013;91(2):148-149. doi:10.2471/BLT.12.109553.
  63. Tsui JI, Evans JL, Lum PJ, Hahn JA, Page K. Association of opioid agonist therapy with lower incidence of hepatitis C virus infection in young adult injection drug users. JAMA Intern Med. 2014;174(12):1974-1981. doi:10.1001/jamainternmed.2014.5416.
  64. Nolan S, Dias Lima V, Fairbairn N, et al. The impact of methadone maintenance therapy on hepatitis C incidence among illicit drug users. Addict Abingdon Engl. 2014;109(12):2053-2059. doi:10.1111/add.12682.
  65. Peles E, Schreiber S, Rados V, Adelson M. Low risk for hepatitis C seroconversion in methadone maintenance treatment. J Addict Med. 2011;5(3):214-220. doi:10.1097/ADM.0b013e31820e13dd.
  66. Alavian SM, Mirahmadizadeh A, Javanbakht M, et al. Effectiveness of Methadone Maintenance Treatment in Prevention of Hepatitis C Virus Transmission among Injecting Drug Users. Hepat Mon. 2013;13(8):e12411. doi:10.5812/hepatmon.12411.
  67. Hallinan R, Byrne A, Amin J, Dore GJ. Hepatitis C virus incidence among injecting drug users on opioid replacement therapy. Aust N Z J Public Health. 2004;28(6):576-578.
  68. Gibson DR, Flynn NM, McCarthy JJ. Effectiveness of methadone treatment in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS Lond Engl. 1999;13(14):1807-1818.
  69. Metzger DS, Woody GE, McLellan AT, et al. Human immunodeficiency virus seroconversion among intravenous drug users in- and out-of-treatment: an 18-month prospective follow-up. J Acquir Immune Defic Syndr. 1993;6(9):1049-1056.
  70. Woody GE, Bruce D, Korthuis PT, et al. HIV risk reduction with buprenorphine-naloxone or methadone: findings from a randomized trial. J Acquir Immune Defic Syndr 1999. 2014;66(3):288-293. doi:10.1097/QAI.0000000000000165.
  71. Bruce RD, Moody DE, Altice FL, Gourevitch MN, Friedland GH. A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practice. Expert Rev Clin Pharmacol. 2013;6(3):249-269. doi:10.1586/ecp.13.18.
  72. Maas B, Kerr T, Fairbairn N, Montaner J, Wood E. Pharmacokinetic interactions between HIV antiretroviral therapy and drugs used to treat opioid dependence. Expert Opin Drug Metab Toxicol. 2006;2(4):533-543. doi:10.1517/17425255.2.4.533.
  73. Zhou W, Wang X, Zhou S, et al. Hepatitis C seroconversion in methadone maintenance treatment programs in Wuhan, China. Addict Abingdon Engl. 2015;110(5):796-802. doi:10.1111/add.12836.
  74. MacArthur GJ, Minozzi S, Martin N, et al. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis. BMJ. 2012;345:e5945.
  75. Carvallo L, Lopez L, Che F-Y, et al. Buprenorphine decreases the CCL2-mediated chemotactic response of monocytes. J Immunol Baltim Md 1950. 2015;194(7):3246-3258. doi:10.4049/jimmunol.1302647.
  76. Fitting S, Zou S, El-Hage N, et al. Opiate addiction therapies and HIV-1 Tat: interactive effects on glial [Ca2+]i, oxyradical and neuroinflammatory chemokine production and correlative neurotoxicity. Curr HIV Res. 2014;12(6):424-434.
  77. Jeffrey GP, MacQuillan G, Chua F, et al. Hepatitis C virus eradication in intravenous drug users maintained with subcutaneous naltrexone implants. Hepatol Baltim Md. 2007;45(1):111-117. doi:10.1002/hep.21470.
  78. Mumola CJ, Karberg JC. Bureau of Justice Statistics Special Report: Drug Use and Dependence, State and Federal Prisoners, 2004. U.S. Department of Justice, Office of Justice Programs; 2006. Accessed May 11, 2017.
  79. Matusow H, Dickman SL, Rich JD, et al. Medication assisted treatment in US drug courts: results from a nationwide survey of availability, barriers and attitudes. J Subst Abuse Treat. 2013;44(5):473-480. doi:10.1016/j.jsat.2012.10.004.
  80. Fiscella K, Moore A, Engerman J, Meldrum S. Jail management of arrestees/inmates enrolled in community methadone maintenance programs. J Urban Health Bull N Y Acad Med. 2004;81(4):645-654. doi:10.1093/jurban/jth147.
  81. Nunn A, Zaller N, Dickman S, Trimbur C, Nijhawan A, Rich JD. Methadone and buprenorphine prescribing and referral practices in US prison systems: results from a nationwide survey. Drug Alcohol Depend. 2009;105(1-2):83-88. doi:10.1016/j.drugalcdep.2009.06.015.
  82. Binswanger IA, Stern MF, Deyo RA, et al. Release from prison–a high risk of death for former inmates. N Engl J Med. 2007;356(2):157-165. doi:10.1056/NEJMsa064115.
  83. Green TC, Clarke J, Brinkley-Rubinstein L, et al. Postincarceration Fatal Overdoses After Implementing Medications for Addiction Treatment in a Statewide Correctional System. JAMA Psychiatry. February 2018. doi:10.1001/jamapsychiatry.2017.4614
  84. Zaller N, McKenzie M, Friedmann PD, Green TC, McGowan S, Rich JD. Initiation of buprenorphine during incarceration and retention in treatment upon release. J Subst Abuse Treat. 2013;45(2):222-226. doi:10.1016/j.jsat.2013.02.005.
  85. World Health Organization. Guidelines for the Psychosocially Assisted Pharmacological Treatment of Opioid Dependence. World Health Organization; 2009. Accessed May 11, 2017.
  86. Friedmann PD, Wilson D, Knudsen HK, et al. Effect of an organizational linkage intervention on staff perceptions of medication-assisted treatment and referral intentions in community corrections. J Subst Abuse Treat. 2015;50:50-58. doi:10.1016/j.jsat.2014.10.001.
  87. Gordon MS, Kinlock TW, Schwartz RP, Fitzgerald TT, O’Grady KE, Vocci FJ. A randomized controlled trial of prison-initiated buprenorphine: prison outcomes and community treatment entry. Drug Alcohol Depend. 2014;142:33-40. doi:10.1016/j.drugalcdep.2014.05.011.
  88. Lee JD, Friedmann PD, Boney TY, et al. Extended-release naltrexone to prevent relapse among opioid dependent, criminal justice system involved adults: rationale and design of a randomized controlled effectiveness trial. Contemp Clin Trials. 2015;41:110-117. doi:10.1016/j.cct.2015.01.005.
  89. Mitchell SG, Willet J, Monico LB, et al. Community correctional agents’ views of medication-assisted treatment: Examining their influence on treatment referrals and community supervision practices. Subst Abuse. 2016;37(1):127-133. doi:10.1080/08897077.2015.1129389.
  90. Brown RT. Systematic review of the impact of adult drug-treatment courts. Transl Res J Lab Clin Med. 2010;155(6):263-274. doi:10.1016/j.trsl.2010.03.001.
  91. Substance Abuse and Mental Health Services Administration. Grants to Expand Substance Abuse Treatment Capacity in Adult and Family Drug Courts: Request for Applications (RFA) No. TI-15-002. 2015.
  92. National Institute on Drug Abuse. Substance Abuse in the Military. Published March 1, 2013. Accessed May 11, 2017.
  93. Shipherd JC, Stafford J, Tanner LR. Predicting alcohol and drug abuse in Persian Gulf War veterans: what role do PTSD symptoms play? Addict Behav. 2005;30(3):595-599. doi:10.1016/j.addbeh.2004.07.004.
  94. Toblin RL, Quartana PJ, Riviere LA, Walper KC, Hoge CW. Chronic pain and opioid use in US soldiers after combat deployment. JAMA Intern Med. 2014;174(8):1400-1401. doi:10.1001/jamainternmed.2014.2726.
  95. U.S. Department of Veteran Affairs. A/DoD Clinical Practice Guideline for the Management of Substance Use Disorders. 2015. Accessed May 11, 2017.
  96. Oliva EM, Trafton JA, Harris AHS, Gordon AJ. Trends in opioid agonist therapy in the Veterans Health Administration: is supply keeping up with demand? Am J Drug Alcohol Abuse. 2013;39(2):103-107. doi:10.3109/00952990.2012.741167.
  97. Gordon AJ, Kavanagh G, Krumm M, et al. Facilitators and barriers in implementing buprenorphine in the Veterans Health Administration. Psychol Addict Behav J Soc Psychol Addict Behav. 2011;25(2):215-224. doi:10.1037/a0022776.
  98. U.S. Department of Defense, Office of the Secretary. TRICARE; Mental Health and Substance Use Disorder Treatment. Federal Register. Published September 2, 2016. Accessed May 11, 2017.
  99. Epstein RA, Bobo WV, Martin PR, et al. Increasing pregnancy-related use of prescribed opioid analgesics. Ann Epidemiol. 2013;23(8):498-503. doi:10.1016/j.annepidem.2013.05.017.
  100. Patrick SW, Dudley J, Martin PR, et al. Prescription opioid epidemic and infant outcomes. Pediatrics. 2015;135(5):842-850. doi:10.1542/peds.2014-3299.
  101. Kaltenbach K, Berghella V, Finnegan L. Opioid dependence during pregnancy. Effects and management. Obstet Gynecol Clin North Am. 1998;25(1):139-151.
  102. The American College of Obstetricians and Gynecologists, The American Society of Addiction Medicine. Opioid Use and Opioid Use Disorder in Pregnancy. The American College of Obstetricians and Gynecologists; 2017. Accessed March 30, 2018.
  103. Effective medical treatment of opiate addiction. National Consensus Development Panel on Effective Medical Treatment of Opiate Addiction. JAMA. 1998;280(22):1936-1943.
  104. Substance Abuse and Mental Health Services Administration. Medication-Assisted Treatment for Opioid Addiction in Opioid Treatment Programs. Treatment Improvement Protocol (TIP) Series 43. Substance Abuse and Mental Health Services Administration; 2005.  Accessed May 11, 2017.
  105. Brogly SB, Saia KA, Walley AY, Du HM, Sebastiani P. Prenatal buprenorphine versus methadone exposure and neonatal outcomes: systematic review and meta-analysis. Am J Epidemiol. 2014;180(7):673-686. doi:10.1093/aje/kwu190.
  106. Kandall SR, Doberczak TM, Jantunen M, Stein J. The methadone-maintained pregnancy. Clin Perinatol. 1999;26(1):173-183.
  107. Jones HE, Kaltenbach K, Heil SH, et al. Neonatal abstinence syndrome after methadone or buprenorphine exposure. N Engl J Med. 2010;363(24):2320-2331. doi:10.1056/NEJMoa1005359.
  108. McCarthy JJ, Leamon MH, Willits NH, Salo R. The effect of methadone dose regimen on neonatal abstinence syndrome. J Addict Med. 2015;9(2):105-110. doi:10.1097/ADM.0000000000000099.
  109. Fajemirokun-Odudeyi O, Sinha C, Tutty S, et al. Pregnancy outcome in women who use opiates. Eur J Obstet Gynecol Reprod Biol. 2006;126(2):170-175. doi:10.1016/j.ejogrb.2005.08.010.
  110. Agency for Healthcare Research and Quality. Mean Expenses per Person with Care for Selected Conditions by Type of Service: United States, 2014. Medical Expenditure Panel Survey Household Component Data. 2016.  Accessed May 11, 2017.
  111. Florence CS, Zhou C, Luo F, Xu L. The Economic Burden of Prescription Opioid Overdose, Abuse, and Dependence in the United States, 2013. Med Care. 2016;54(10):901-906. doi:10.1097/MLR.0000000000000625.
  112. Jones CM, Lurie PG, Compton WM. Increase in Naloxone Prescriptions Dispensed in US Retail Pharmacies Since 2013. Am J Public Health. 2016;106(4):689-690. doi:10.2105/AJPH.2016.303062.
  113. Davis CS, Southwell JK, Niehaus VR, Walley AY, Dailey MW. Emergency medical services naloxone access: a national systematic legal review. Acad Emerg Med Off J Soc Acad Emerg Med. 2014;21(10):1173-1177. doi:10.1111/acem.12485.
  114. Ray B, O’Donnell D, Kahre K. Police officer attitudes towards intranasal naloxone training. Drug Alcohol Depend. 2015;146:107-110. doi:10.1016/j.drugalcdep.2014.10.026.
  115. Walley AY, Xuan Z, Hackman HH, et al. Opioid overdose rates and implementation of overdose education and nasal naloxone distribution in Massachusetts: interrupted time series analysis. BMJ. 2013;346:f174.
  116. Doe-Simkins M, Quinn E, Xuan Z, et al. Overdose rescues by trained and untrained participants and change in opioid use among substance-using participants in overdose education and naloxone distribution programs: a retrospective cohort study. BMC Public Health. 2014;14:297. doi:10.1186/1471-2458-14-297.
  117. Enteen L, Bauer J, McLean R, et al. Overdose prevention and naloxone prescription for opioid users in San Francisco. J Urban Health Bull N Y Acad Med. 2010;87(6):931-941. doi:10.1007/s11524-010-9495-8.
  118. Behar E, Santos G-M, Wheeler E, Rowe C, Coffin PO. Brief overdose education is sufficient for naloxone distribution to opioid users. Drug Alcohol Depend. 2015;148:209-212. doi:10.1016/j.drugalcdep.2014.12.009.
  119. Coffin PO, Sullivan SD. Cost-effectiveness of distributing naloxone to heroin users for lay overdose reversal. Ann Intern Med. 2013;158(1):1-9. doi:10.7326/0003-4819-158-1-201301010-00003.